{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-functional/prescribing-information/amoxicillin/","result":{"pageContext":{"chapter":{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin","depth":2,"htmlHeader":"<!-- begin field 8cb93da1-d969-4eea-a795-a7470164ce38 --><h2>Amoxicillin</h2><!-- end field 8cb93da1-d969-4eea-a795-a7470164ce38 -->","summary":"","htmlStringContent":"<!-- begin item d3363db1-9b30-4fb7-b2b8-a7470164cf48 --><!-- end item d3363db1-9b30-4fb7-b2b8-a7470164cf48 -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","lastRevised":"Last revised in October 2018","chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","fullItemName":"Management","slug":"management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"eedfa938-6c85-5d3a-9621-4da71b716d2f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0fffa814-3c34-49d6-8696-a74a00e658f9 --><h3>Contraindications and cautions</h3><!-- end field 0fffa814-3c34-49d6-8696-a74a00e658f9 -->","summary":"","htmlStringContent":"<!-- begin item 93d8d2df-9b93-44cf-a412-a74a00e65896 --><!-- begin field 3ea25155-8f80-4247-adc2-a74a00e658f9 --><ul><li><strong>Do not prescribe amoxicillin to people with:</strong><ul><li>A true penicillin hypersensitivity – gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin.</li><li>History of penicillin-associated hepatic dysfunction.</li></ul></li><li><strong>Prescribe amoxicillin with caution to people with:</strong><ul><li>Hypersensitivity to cephalosporins.</li><li>Hepatic impairment.</li><li>Chronic kidney disease (CKD) stages 4 or 5 — reduce the dose of amoxicillin.<ul><li>If the estimated glomerular filtration rate (eGFR) is 10–30 mL/minute/1.73 m<sup>2</sup>, prescribe a maximum of 500 mg twice a day.</li><li>If the eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, prescribe a maximum of 500 mg once a day.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>] </p><!-- end field 3ea25155-8f80-4247-adc2-a74a00e658f9 --><!-- end item 93d8d2df-9b93-44cf-a412-a74a00e65896 -->","subChapters":[]},{"id":"a0aab6bf-0fab-51b5-a57c-36de505c2a37","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e97abb8b-74c8-4aa0-ba76-a74a00e66df6 --><h3>Adverse effects</h3><!-- end field e97abb8b-74c8-4aa0-ba76-a74a00e66df6 -->","summary":"","htmlStringContent":"<!-- begin item 60dbb60a-1880-444c-8f0f-a74a00e66c32 --><!-- begin field 13d3e680-64eb-412c-adc2-a74a00e66df6 --><ul><li>The most common adverse effects of penicillins include diarrhoea, nausea, vomiting, and skin rash.</li><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with amoxicillin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li><li>Anaphylaxis (immediate or delayed) is a serious but rare adverse effect of amoxicillin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>] </p><!-- end field 13d3e680-64eb-412c-adc2-a74a00e66df6 --><!-- end item 60dbb60a-1880-444c-8f0f-a74a00e66c32 -->","subChapters":[]},{"id":"4ae3ca82-4411-5f56-8ab1-2ad5998b61b9","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 369e005e-c6e9-4551-a1d3-a74a00e680c2 --><h3>Drug interactions</h3><!-- end field 369e005e-c6e9-4551-a1d3-a74a00e680c2 -->","summary":"","htmlStringContent":"<!-- begin item e68d8427-f030-4157-9f3b-a74a00e6802d --><!-- begin field de876f6d-17e9-4409-9fd7-a74a00e680c2 --><p><strong>Possible drug interactions with amoxicillin include:</strong></p><ul><li><strong>Allopurinol </strong>— concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes. Concomitant use need not be avoided for this reason.</li><li><strong>Anticoagulants (for example warfarin) </strong>— monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary. Prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.</li><li><strong>Methotrexate </strong>— monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected. Penicillins may reduce the excretion of methotrexate, however clinically this is not usually serious.</li><li><strong>Tetracyclines </strong>— effect of penicillins possibly antagonized by tetracyclines.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field de876f6d-17e9-4409-9fd7-a74a00e680c2 --><!-- end item e68d8427-f030-4157-9f3b-a74a00e6802d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}